ArticleBritish journal of cancer2018

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.

Stéphanie M Zunder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.